Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas

Presenters: Ayrin Kök, Germain Margallducos, Stephanie Beq, Clarisse Monchecourt, Hombline Poullain, Muriel David, Sami Ellouze, Carine George, Mingjie Chen, Yun-Yueh Lu, Juying Li, Qian Zhang, Jean Wang, Adam Woolfe, Louise Gody, Francisco Adrian, Liang Schweizer, Nicola Beltraminelli

HFB1002 program focuses on the development of monoclonal antibodies against human CXCR5 as a novel treatment for B-cell lymphoma and several autoimmune disorders.

More information about these and other programs in the HiFiBiO Therapeutics pipeline is available at